Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia

Tremor and Other Hyperkinetic Movements

Volumn 1, Issue 1, 2013, Pages

  Fernandez, Hubert H ^a   Pappert, Eric J ^b   Comella, Cynthia L ^c   Evidente, Virgilio Gerald H ^d   Truong, Daniel D ^e   Verma, Amit ^b   Jankovic, Joseph ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Merz Pharmaceuticals LLC   (United States)

^c RUSH UNIVERSITY   (United States)

^d Howe Industries   (United States)

^e Parkinson's and Movement Disorder Institute   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Botulinum toxin type A; Cervical dystonia; IncobotulinumtoxinA; Pretreated; Treatment na ve

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

ADULT; AGED; APPENDICITIS; ARTICLE; ASTHMA; CERVICAL DYSTONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STAPHYLOCOCCUS INFECTION;

EID: 85202532818     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-194, http://dx.doi.org/10.1002/mds.870030302.
2. Crowner BE. Cervical dystonia: disease profile and clinical management. Phys Ther2007;87:1511-1526, http://dx.doi.org/10.2522/ptj.20060272.
3. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5-18, http://dx.doi.org/10.1111/j.1468-1331.2010.03042.x.
4. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006;67:2230-2232, http://dx.doi.org/10.1212/01.wnl.0000249310.25427.f2.
5. Frevert J. Xeomin is free from complexing proteins. Toxicon 2009;54:697-701, http://dx.doi.org/10.1016/j.toxicon.2009.03.010.
6. Merz Pharmaceuticals, LLC. XEOMIN-(incobotulinumtoxinA) for injection US Prescribing Information. 2011:Version 07/2011.
7. Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308:103-109, http://dx.doi.org/10.1016/j.jns.2011.05.041.
8. Consky E, Basinski A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (Abstract 1199P). Neurology. 1990;40.
9. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc.; 1994. p 211-237.
10. Wissel J, Muller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-49, http://dx.doi.org/10.1016/S0885-3924(00)00146-9.
11. Evidente VG, Fernandez HH, LeDoux MS, et al. Efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in subjects with cervical dystonia: a randomized, double-blind extension study. Mov Disord 2012; under consideration.